Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ottawa Hospital Research Institute
With
Multiple Sclerosis Scientific Research Foundation
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age between 18 and 50 years
The diagnosis of active multiple sclerosis with relapses or progression and sustained accumulated impairment, made by a neurologist expert in the field
Patient considered at high risk of progression
EDSS Cerebellar Functional score greater than or equal to 3 OR EDSS Pyramidal Functional score greater than or equal to 3
EDSS between greater than or equal to 3 and less than or equal to 6
Evidence of current disease activity
Evidence of progression or continued relapses or worsening MRI after at least one year of therapy with interferon-B1, glatiramer acetate, Mitoxantrone, or other conventional dose immunosuppressive drug therapy
If a patient has previously received a cytotoxic agent (Mitoxantrone, Cyclophosphamide etc.) they must have normal bone marrow morphology and cytogenetics before being considered eligible for this study
MRI brain scan that satisfies the MRI criteria of Paty or Fazekas for the diagnosis of multiple sclerosis
No evidence of hepatic inflammation or fibrosis
You may not be if
Patients with primary progressive multiple sclerosis
Patients with cardiac, renal, pulmonary, hepatic or other organ impairment that would limit their ability to receive dose intensive immunosuppressive therapy including high dose chemotherapy and ASCT
Patient with any active or chronic infection
Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C
Patients with a previous history of a malignancy other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year
Patients whose life expectancy is severely limited by another co-morbid illness
Patients with evidence of myelodysplasia or other non-autoimmune cytopenia
Patients having received a cytotoxic agent within one month of enrolling in this study
Pregnancy or risk of pregnancy. This includes patients that are unwilling to practice active contraception during the time of chemotherapy
Patients with hypersensitivity to rabbit proteins
Patients unable to give written informed consent in accordance with research ethics board guidelines
Patients having previous exposure to natalizumab or alemtuzumab.
Clareo Health | Autologous Stem Cell Transplant for Multiple Sclerosis
